Life Sciences News | BioTuesdays by Kilmer Lucas IR

Executive Moves

Tatjana Mitchell joins Evolus as CFO

Evolus (NASDAQ: EOLS) has announced the appointment of Tatjana Mitchell as chief financial officer (CFO), effective today. Ms. Mitchell brings more than 20 years of strategic and operational finance leadership across...

September 8, 2025

Developments

Pasithea enrolls Cohort 2 for trial of PAS-004 in NF1 after SRC review

Pasithea Therapeutics (NASDAQ: KTTA) announced that the Safety Review Committee (SRC) has recommended its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PAS-004...

September 8, 2025

Developments

Firefly partners with HealingMaps to offer cognitive electrophysiology analytics to 2500+ clinics across North America

Firefly Neuroscience (NASDAQ: AIFF) announced a new partnership with HealingMaps the leading directory for ketamine, psychedelic-assisted therapy, and transcranial magnetic stimulation (TMS) clinics, and Advanced...

September 5, 2025

Developments

Health Canada grants Palisade NOL for trial of PALI-2108 in FSCD

Palisade Bio (NASDAQ: PALI) has announced receiving a No Objection Letter (NOL) from Health Canada for its clinical trial application to evaluate PALI-2108, a first-in-class, ileocolonic-targeted PDE4 B/D inhibitor, in...

September 5, 2025

Developments

AIM highlights compelling data for Ampligen in PC at conference in Poland

AIM ImmunoTech (NYSE American: AIM) announced the latest in a growing body of positive data from its lead clinical program, Ampligen, for the treatment of pancreatic cancer (PC), in a presentation at the 5th Annual...

September 5, 2025

Executive Moves

Dr. Thomas J. Errico elected electroCore’s chairman of the board; Peter Cuneo retires

electroCore (NASDAQ: ECOR) has announced the election of Thomas J. Errico, MD, as chairman of the board and the departure of Peter Cuneo from its board of directors (BOD). According to electroCore, Mr. Cuneo will...

September 5, 2025

Developments

Vyome announces positive interim data on VT-1953 in MFW

Vyome Holdings (NASDAQ: HIND) has announced the interim results from its investigator –initiated Phase 2 Proof of Concept study of VT-1953 topical gel in patients with malignant fungating wounds (MFW). According to...

September 4, 2025

Developments

Lyell initiates Phase 3 CAR T-cell therapy trial in R/R LBCL; forms expert steering committee

Lyell Immunopharma (NASDAQ: LYEL) has announced the initiation of PiNNACLE—H2H, a Phase 3 head-to-head CAR T-cell therapy randomized controlled trial evaluating rondecabtagene autoleucel (ronde-cel, also known as...

September 3, 2025

Executive Moves

Adagene appoints Dr. Axel Hoos as executive advisor

Adagene (NASDAQ: ADAG) has announced the appointment of immuno-oncology pioneer, Axel Hoos, MD, PhD, as executive advisor. Most recently, Dr. Hoos served as CEO of Scorpion Therapeutics, which was acquired by Eli Lilly...

September 3, 2025

Executive Moves

Dr. Barbara Krebs-Pohl joins CASI’s BOD

CASI Pharmaceuticals (NASDAQ: CASI) has announced the appointment of Barbara Krebs-Pohl, PhD, as an independent director to its board of directors (BOD). Dr. Krebs-Pohl brings more than 27 years of leadership experience...

September 2, 2025

Developments

Oncolytics reveals updated safety data for pelareorep in GI tumors

Oncolytics Biotech (NASDAQ: ONCY) has announced that data continues to demonstrate a favorable safety profile for intravenously administered pelareorep across multiple gastrointestinal (GI) tumors, and in combination...

September 2, 2025

Developments

Providence Saint Joseph Medical Center acquires Perimeter’s OCT imaging technology

Providence Saint Joseph Medical Center—a nationally recognized, 383-bed, not-for-profit hospital in Burbank, California— has announced that it has adopted Perimeter Medical Imaging AI’s (TSXV: PINK; OTCQX: PYNKF)...

August 29, 2025

Subscribe